Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;90(1):145-154.
doi: 10.1111/cen.13862. Epub 2018 Oct 23.

Serum testosterone, sex hormone-binding globulin and sex-specific risk of incident type 2 diabetes in a retrospective primary care cohort

Affiliations

Serum testosterone, sex hormone-binding globulin and sex-specific risk of incident type 2 diabetes in a retrospective primary care cohort

Michael W O'Reilly et al. Clin Endocrinol (Oxf). 2019 Jan.

Abstract

Objective: Previous studies suggest that androgens have a sexually dimorphic impact on metabolic dysfunction. However, the sex-specific link between circulating androgens and risk of type 2 diabetes mellitus (T2DM) has not been examined in a large scale, longitudinal cohort, a task we undertook in this study.

Design: A retrospective cohort study in a UK primary care database.

Patients: We included men and women with available serum testosterone and sex hormone-binding globulin (SHBG) results.

Measurements: We categorized serum concentrations according to clinically relevant cut-off points and calculated crude and adjusted T2DM Incidence Rate Ratios (IRRs and aIRRs).

Results: Serum testosterone concentrations were available in 70 541 men and 81 889 women; serum SHBG was available in 15 907 men and 42 034 women. In comparison to a reference cohort with serum testosterone ≥20 nmol/L, men with lower serum testosterone had a significantly increased risk of T2DM, with the highest risk in those with serum testosterone <7 nmol/L (aIRR 2.71, 95% CI 2.34-3.14, P < 0.001). In women, the risk of T2DM started to increase significantly when serum testosterone concentrations exceeded 1.5 nmol/L, with the highest risk in women with serum testosterone ≥3.5 nmol/L (aIRR 1.98, 95% CI 1.55-2.52, P < 0.001). These observations were verified in a continuous rather than categorized analysis. The risk of T2DM increased in men and women with serum SHBG <40 and <50 nmol/L, respectively.

Conclusions/interpretation: In this longitudinal study, we found sexually dimorphic associations between serum testosterone and risk of incident T2DM. Androgen deficiency and excess should be considered important risk factors for diabetes in men and women, respectively.

Keywords: androgens; diabetes; hypogonadism; metabolic diseases; population health; sex hormone-binding globulin; testosterone.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Risk of incident type 2 diabetes (T2DM) according to serum testosterone and sex hormone‐binding globulin (SHBG) concentration categories in men. A, Adjusted Incidence Rate Ratios (aIRRs) for diabetes in 70 541 men with serum testosterone measurements. B, Distribution of 70 541 men across each quintile of serum testosterone concentration. C, aIRRs for serum SHBG concentrations for incident diabetes in 15 907 men. D, Distribution of 15 907 men across each category of serum SHBG concentration. [Correction added on 14 November 2018, after first online publication: in panel D, an error in the data for 40‐49.99 nmol/L has been corrected.]
Figure 2
Figure 2
Risk of incident type 2 diabetes (T2DM) according to serum testosterone and sex hormone‐binding globulin (SHBG) concentrations in women. A, Adjusted Incidence Rate Ratios (aIRRs) for incident diabetes in 81 889 women with serum testosterone measurements. B, Distribution of 81 889 women across each category of serum testosterone concentration. C, aIRRs for serum SHBG concentrations for incident diabetes in 42 034 women with serum SHBG measurements. D, Distribution of 42 034 women across each category of serum SHBG concentration. [Correction added on 14 November 2018, after first online publication: in panel B, missing data for 3–3.49 and ≥3.5 nmol/L have been added.]

Similar articles

Cited by

References

    1. Kautzky‐Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev. 2016;37(3):278‐316. - PMC - PubMed
    1. Schiffer L, Kempegowda P, Arlt W, O'Reilly MW. MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease. Eur J Endocrinol. 2017;177(3):R125–R143. - PMC - PubMed
    1. Kumarendran B, O'Reilly MW, Manolopoulos KN, et al. Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: a longitudinal study based on a United Kingdom primary care database. PLoS Med. 2018;15(3):e1002542. - PMC - PubMed
    1. O'Reilly MW, Kempegowda P, Walsh M, et al. AKR1C3‐mediated adipose androgen generation drives lipotoxicity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2017;102(9):3327‐3339. - PMC - PubMed
    1. Maraka S, Singh Ospina N, Rodriguez‐Gutierrez R, et al. Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta‐analysis. J Clin Endocrinol Metab. 2017;102(11):3914‐3923. - PubMed

Publication types